We scan new podcasts and send you the top 5 insights daily.
Banerjee has not told patients to avoid exercise and has not seen symptomatic muscle or cardiac events from CPK elevation. She manages it by grade in her practice: pause grade 3 until recovery, then resume the same dose; grade 4 may require dose reduction or stopping.
Banerjee notes FDA interest in echocardiograms with MEK inhibitors, and RAMP 301 introduced them. Even an asymptomatic patient doing well should get an echo, she says, because cardiac dysfunction can be managed by pausing the drug, treating with cardiology input, and restarting when ejection fraction improves.
Peripheral edema from MET inhibitors like capmatinib or tepotinib is cumulative and unavoidable over long-term treatment. Dr. Liu notes that diuretics merely elevate creatinine and compression stockings simply displace fluid. Instead of continuing until disease progression, clinicians should reduce doses and implement temporary treatment breaks until swelling recedes to an acceptable baseline, resuming therapy before tumor progression occurs.
An observed signal for cardiac dysfunction in the Lenvatinib-Belzutifan arm of a recent trial is causing concern among clinicians. The lack of detailed characterization for this toxicity makes it a significant point of discussion and an area requiring more data before the regimen's safety profile is fully understood.
To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.
For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.
Susanna Banerjee explained that elevated creatine phosphokinase from avutometinib and defactinib represents an asymptomatic biochemical rise rather than cardiac damage or rhabdomyolysis. Trialists initially set overly strict dose interruption guidelines before recognizing patients had no corresponding muscle symptoms.
A key clinical strategy for managing the TKI Zongertinib is proactive liver function monitoring. Checking AST/ALT every two weeks for the first three months allows clinicians to intervene with dose holds at the first sign of mild elevations, thereby preventing severe toxicity that would mandate a dose reduction.
Clinicians should interpret anemia in myelofibrosis patients on JAK inhibitors based on its timing. Anemia in the first 16 weeks is an expected on-target effect. In contrast, new anemia in a patient on a stable dose is a warning sign that may indicate disease progression, warranting further investigation.
CPK elevation is a frequent lab finding with avutametinib but is almost always asymptomatic and doesn't cause clinical muscle weakness. This understanding has led to less stringent criteria for drug discontinuation, allowing more patients to remain on effective therapy despite the biomarker change.
Clinicians should not halt abemaciclib for a mild rise in creatinine, as it's often a spurious lab finding due to altered tubular secretion, not renal injury. Ordering a cystatin C test can confirm normal kidney function, allowing patients to safely continue treatment.